"10.1371_journal.pone.0097139","plos one","2014-05-23T00:00:00Z","Derek M Erion; Amanda Lapworth; Paul A Amor; Guoyun Bai; Nicholas B Vera; Ronald W Clark; Qingyun Yan; Yimin Zhu; Trenton T Ross; Julie Purkal; Matthew Gorgoglione; Guodong Zhang; Vinicius Bonato; Levenia Baker; Nicole Barucci; Theresa Dâ€™Aquila; Alan Robertson; Robert J Aiello; Jiangli Yan; Jeff Trimmer; Timothy P Rolph; Jeffrey A Pfefferkorn","Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, Cambridge, Massachusetts, United States of America; Groton Center of Chemistry, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America","Conceived and designed the experiments: DME AL PAA GB NBV RWC QY YZ GZ VB LB NB AR RJA JY JT TPR JAP. Performed the experiments: DME AL PAA GB NBV RWC QY YZ TTR JP MG GZ VB LB NB TD AR JY. Analyzed the data: DME AL GB NBV RWC GZ VB LB NB AR. Wrote the paper: DME AL NBV VB AR TPR JAP.","We have the following interests. All authors were employees of Pfizer during the completion and analyses of these studies. Pfizer has provided all funding for these studies. PF-04991532 was published in the following patent: US 7,977,367 and was being developed for type 2 diabetes. All current trials for PF-04991532 have been halted at this time. As mentioned in the review, Pfizer is making PF-04991532 commercially available through Sigma-Aldrich and is also happy to provide it free of charge through our Compound Gift Program. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","05","Derek M Erion","DME",22,TRUE,18,18,10,7,TRUE,TRUE,FALSE,0,NA,FALSE
